Dr. John L. Faessel
ON THE MARKET
Commentary and Insights
A Best Idea UPDATE for 2011 & More on the Ultimate Test – On Me...
I’ve Tried It and It Works
Star Scientific Inc. (CIGX) $3.86 Nasdaq
I think the market gave us another ‘freebie’ entry point here.
Yesterday the stock market experienced its sixth straight down day that sliced about 5% off the major indexes; the selloff capped the worst down-leg in a year. Moreover the shares of Star Scientific (CIGX) closed down along with the market to what I believe is a very favorable entry point as shares closed at $3.86.
Let's first note that that an 8-K filing from March 30 tells us that Robert Roskamp, the Director of the Roskamp Institute bought $1,000,000 of “additional” stock and warrants at $4.00.* Certainly, if the director of the Institute, who must know more about how their research is going bought more stock it's pretty clear to me that this would be a good place to add to positions or institute a new position if you weren't already a shareholder.
Importantly that “buy” by Mr. Roskamp adds to last year’s $1,000,000 purchase of 769,000 shares and the rights / warrants to buy another million shares at $1.30.
To further hammer home the belief that this is a good entry point is that the successes of the Roskamp Institute's research is light-years ahead of where it was last March. Last month the Roskamp Institute posted an Update on 'inflammaging' research at the Roskamp Institute. The data demonstrates the anti-inflammatory properties of (RCP-006) in comparison to NSAIDs in whole human blood.
The graph demonstrates vividly how (RCP-006) is more than four (4) times more effective than either Celebrex or Voltarol in reducing inflammation. Both Celebrex and Voltarol are powerful non-steroidal anti-inflammatory drugs, have helped millions of people and have sold in the billions of dollars. Unfortunately recent news of major side effects has affected their sales to large degree. Both are drugs that require prescriptions from a physician. Also vital in this analysis is that previous research from a few months ago demonstrated the dramatic effect of anatabine (RCP-006) versus Lipitor, well known to have advanced anti-inflammatory properties. (RCP-006) was shown to be more than three (3) times more effective than Lipitor in reducing inflammation. Lipitor sales in 2010 were $10.7 billion.
Just grasp the market for an over-the-counter item, (a nutritional supplement) that could have these astonishing successes; it's of mind-boggling proportions.
In one of my reports last year on Star Scientific (shares were $1.67 at the time) I spoke of how CigRx™ was so successful in quelling my urge to smoke cigars; and it continues to do just that. Now, since I was "sampled" with Star Scientific’s product (RCP-006) Anatabloc™ (that’s used in the studies at Roskamp, Johns Hopkins, and in the Flint Study) I thought I would give you an update on my personal experience with the compound.
I've been taking the product for about two months now and have increased my dosage to about 10 of the tabs a day. I began by taking about six a day. My experience is that while I've yet to compare with previous blood tests to see its effect on a long-standing hypothyroid condition yet and that I will do next month, I can tell you that I have had dramatic improvement in dealing with my enlarged prostate [BPH] condition. My physician tells me that my prostate is healthy, soft, noncancerous, but quite enlarged. The condition “BPH” causes a number of bothersome symptoms that I'll let you link to via the hyperlink. Anyway, the short version is I only have to get up a couple of times a night and the ease of flow of urine is hugely improved. It's remarkable.
My wife also takes the Anatabloc ™ for the rheumatoid arthritis centered in her hands and she has experienced less swelling, less pain and increased mobility. We are both extremely pleased with the results to put it mildly. Understandably, these are anecdotal stories about the compound success, but when they are personal it takes on another dimension. In both our cases this product we believe has improved our life, and I might add that we both feel a bit more spry.
Because I've been writing about Star Scientific for about a year now I am pretty accessible to those people, their loved ones and investors who have taken Star’s products. From these people I've heard numerous anecdotal stories of the extraordinary successes of the (RCP-006) compound. They include major improvements in rheumatoid arthritis, carpal tunnel syndrome, dementia, irritable bowel syndrome, Crohn's disease, thyroid conditions and other assorted conditions related to aging. Obviously, something is going on here. And when you access and read that recent Roskamp research about (RCP-006) Anatabloc ™ Update on 'inflammaging' research at the Roskamp Institute it becomes pretty clear that there will soon be a very effective new way to deal with some very nasty medical conditions on the market.
Star Scientific’s product, (RCP-006) targets low grade inflammations that is present in a number of coronary and vascular diseases, and in auto-immune diseases such as thyroid disease, diabetes and arthritis and numerous other conditions.
The Roskamp Institute funded by the National Institutes of Health and private donations, is conducting research using (RCP-006) on Alzheimer’s disease, gastroenterology, rheumatology, cancer, auto-immune diseases (lupus), and cardio-atherogenesis (the process of atheromatous plaque development in arteries), among other conditions.
I just received a link to and article in the Sarasota Herald-Tribune that I hadn't seen before: http://www.heraldtribune.com/article/20110521/ARTICLE/110529811?p=all&tc=pgall&tc=ar him
Another notable metric mentioned at the Roskamp meeting is that about 100,000 people have now taken (RCP-006) compounds.
Check out the web-site that describes CigRx™ and how to purchase the lozenges. The site has an exceptional and professional look with testimonials and video links―It's a powerful sell. The website, www.cigrx.com
Disclaimer: I'm an investor in Star Scientific Inc. (CIGX) shares and have no other affiliation with the company than as a shareholder. I have purchased shares of Star Scientific in the open market.
To view the (CIGX) website: http://www.starscientific.com
* On March 30, 2011, Star Scientific, Inc. (the "Company") entered into a Securities Purchase and Registration Rights Agreement (the "March 30 Agreement") with an accredited investor (the "March 30 Investor") to sell 254,452 shares (the "March 30 Shares") of the Company's common stock, par value $0.0001 per share ("Common Stock"), at $3.93 per share and warrants to purchase an aggregate of 254,452 shares of Common Stock at an exercise price of $4.00 per share (the "Warrants") (collectively, the "March 30 Offering"). The March 30 Offering resulted in gross proceeds to the Company of $1,000,000. The Warrants are first exercisable on September 30, 2011 and expire on September 30, 2016.
THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, Robert G. Roskamp (the “Holder”), is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after September 30, 2011 (the “Initial Exercise Date”) and on or prior to the close of business on September 30, 2016 (the “Termination Date”) but not thereafter (the “Exercise Period”), to subscribe for and purchase from Star Scientific, Inc.,